期刊
CADERNOS DE SAUDE PUBLICA
卷 37, 期 10, 页码 -出版社
CADERNOS SAUDE PUBLICA
DOI: 10.1590/0102-311X00304420
关键词
Pharmacovigilance; Drug-Related Side Effects and Adverse Reactions; Adverse Drug Reaction Reporting System; Drug Monitoring
The study showed that the Porto Pharmacovigilance Centre (UFPorto) has received a substantial number of notifications regarding suspected adverse drug reactions over its two decades of work, with most coming from hospital institutions and physicians. The majority of adverse events were classified as severe and are typically described in the Summary of Product Characteristics. The causality of the reported adverse drug reactions was predominantly considered as probable.
Since 1963, the World Health Organization has acknowledged pharmacovigilance as a priority area in global public health, guaranteeing permanent monitoring of drug safety. This study aimed to characterize the reports of adverse drug reactions received by the Porto Pharmacovigilance Centre (UFPorto), Portugal, in the unit's two decades of work. The analysis included all reports of suspected adverse drug reactions received from January 2001 to December 2019. We calculated the annual reporting rates and distribution by origin, type of notifier and place of work, severity, prior knowledge, and causality of the reported adverse drug reactions. During the study period, UFPorto received 9,711 notifications of suspected adverse drug reactions. Hospital institutions reported the most suspected adverse drug reactions (n = 6,003; 64%), as did physicians among healthcare workers (n = 5,284; 54.4%). The most frequently reported adverse events were severe (n = 6,275; 72%) and are described in the respective Summary of Product Characteristics (n = 6,978; 72%). Most of the reports received by UFPorto were evaluated as having probable causality (n = 7,473; 77%), independently of the type of notifier. The results are consistent with other data previously reported in the international medical literature and official national reports. However, the underreporting rates are still higher than expected. In approximately 20 years, UFPorto has experienced an increase in its activity in various areas of drug safety.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据